CA Patent

CA2405745A1 — New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2001-11-08 · 25y expired

What this patent protects

The invention relates to betamimetics of the general formula (1), wherein R1 represents a group (a), where R3 represents benzyl which can optionally be substituted by methoxy, R4 represents hydrogen, or R3 and R4 conjointly represent a -CO-CH2-O- bridge, whereby the carbonyl grou…

USPTO Abstract

The invention relates to betamimetics of the general formula (1), wherein R1 represents a group (a), where R3 represents benzyl which can optionally be substituted by methoxy, R4 represents hydrogen, or R3 and R4 conjointly represent a -CO-CH2-O- bridge, whereby the carbonyl group of this bridge is bonded to the nitrogen; R2 represents a group selected from (b) and (c), whereby R5 represents dimethylamino, methoxy or butoxy, X represents a nitrogen or a carbon, R6 represents methoxyphenyl if X is nitrogen, or if X is carbon, an annellated phenyl ring likewise linked to X. The invention also relates to a method for the production of said betamimetics and to their use as medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
CA2405745A1
Jurisdiction
CA
Classification
Expires
2001-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.